Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics

This technology relates to multimeric bacterial protein toxins which can be used to specifically target cells. Specifically, this is a modified recombinant anthrax toxin protective antigen (PrAg) that has been modified in several ways. First, the PrAg can be activated both by a metalloproteinase (MMP) and by urokinase plasminogen activator (uPA). Second, the native PrAg lethal factor (LF) binding site has been modified so that only a modified PrAg comprising two different monomers can bind anthrax LF. When administered with an effector component, the recombinant anthrax toxins are toxic only to cells expressing both a MMP and uPA on their surface. This technology is therefore useful for selective methods of treating cancers, because many cancer cells express multiple cell-surface proteases.IC: NIAIDNIH Ref. No.: E-059-2004/0TAB No: TAB-996Provider Technology ID: 996Updated On: Jul 6, 2017Provider Classifications: Date Published: Thursday, July 6, 2017Patent Application: 60/543,41711/055,557PCT/US2005/0421613/088,011Publications: Patent Authority: EIRUSUSPCTUSPatent Number: 7,947,2898,388,933Licensing Contacts: Lead Inventor: Inventor IC: NIAIDNIAIDNIDCRInventor Lab URL: http://irp.nih.gov/pi/stephen-lepplahttp://irp.nih.gov/pi/thomas-buggeLPM FIrst Name: WadeLPM Last Name: GreenLPM Address: BG 5601FL RM 2G56 MSC 9804
5601 FISHERS LNLPM City: BethesdaLPM Zip: 20892-9804Inv Is le...

Source: NIH OTT Licensing Opportunities - July 6, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research